Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis

Neoplasma

Volumn 52, Issue 2, 2005, Pages 119-125

  Moravcova J ^a   Regner, J ^a   Mouckova D ^a   Fiser K ^a   Zmekova V ^a   Malacova R ^a   Michalova K ^a   Klamova H ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

BCR ABL; BCR ABL BCR; CML; Disease prognosis; Disease status; Quantitative RT PCR

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; HYDROXYUREA; IMATINIB;

ADULT; AGED; ARTICLE; BCR GENE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; PATHOGENESIS; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 17044386914     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. ARLINGHAUS RB. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia. Oncogene 2002; 21: 8560-8567.
2. BEILLARD E, PALLISGAARD N, VAN DER VELDEN VH, BI W, DEE R et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - A Europe Against Cancer Program. Leukemia 2003; 17: 2474-2486.
3. BRANFORD S, HUGHES TP, RUDZKI Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587-599.
4. CROSS NCP, FENG L, CHASE A, BUNGEY J, HUGHES TP et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
5. DALEY GQ, VAN ETTEN RA, BALTIMORE D. Induction of chronic myeloid leukemia by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
6. EMIG M, SAUSSELE S, WITTOR H, WEISSER A, REITER A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real-time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
7. GABERT J, BEILLARD E, VAN DER VELDEN VH, BI W, GRIMWADE D et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
8. GAIGER A, HENN T, HORTH E, GEISSLER K, MITTERBAUER G et al. Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371-2378.
9. GUO JQ, LIN H, KANTARJIAN H, TALPAZ M, CHAMPLIN R et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002; 16: 2447-2453.
10. HAWK N, LIU J, SUN T, WANG Y, WU Y et al. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Blood 2001; 98b: 167.
11. HOCHHAUS A, LIN F, REITER A, SKLADNY H, MASON PJ et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
12. JONES CD, YEUNG C, ZEHNDER JL. Comprehensive validation of real-time quantitative bcr-abl assay for clinical laboratory use. Am J Clin Pathol 2003; 20: 42-48.
13. LIN F, MONACO G, SUN T, LIU J, LIN H et al. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Oncogene 2001; 20: 1873-1881.
14. LION T, HENN T, GAIGER A, KALHS P, GADNER H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukemia. Lancet 1993; 341: 275-276.
15. LIU J, WU Y, ARLINGHAUS RB. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 1996; 56: 5120-5124.
16. MORAVCOVÁ J, LUKÁŠOVÁM, STARÝ J, HAŠKOVEC C. Simple competitive two-step RT-PCR assay to monitor minimal residual disease in CML patients after bone marrow transplantation. Leukemia 1998; 12: 1303-1312.
17. MORAVCOVÁ J, MUCHOVÁ S, KALBÁČOVÁ R, HAŠKOVEC C. Single-tube quantitative RT-PCR for monitoring of the response to IFN treatment in CML patients. Leukemia 1998; 12: 1326-1327.
18. MORAVCOVÁ J, MUCHOVÁ S, LUKÁŠOVÁ M, KLAMOVÁ H, BŘEZINOVÁ J et al. Late molecular relapse in two CML patients in molecular remission after donor lymphocyte transfusion for post-BMT relapse. Bone Marrow Transplant 1999; 23: 857-859.
19. MORAVCOVÁ J, NÁDVORNÍKOVÁ S, LUKÁŠOVÁ M, KLAMOVÁ H. Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia. Blood 1999; 94: 3609-3611.
20. MORAVCOVÁ J, ZMEKOVÁ V, KLAMOVÁ H, VOGLOVÁ J, FABER E et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leukemia Res 2004; 28: 415-419.
21. SAWYERS CL, MC LAUGHLIN J, GOGA A, HAVLIK M, WITTE O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 1994; 77: 121-131.
22. WU Y, MA G, LU D, LIN F, XU HJ et al. Bcr: a negative regulator of the Bcr-Abl oncoprotein. Oncogene 1999; 18: 4416-4424.
23. YUAN ZM, SHIOYA H, ISHIKO T, SUN X, GU J et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999; 399: 814-817.